<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2101210448
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Refixia
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        NONACOG BETA PEGOL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1000
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder and solvent for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        6105.70
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Novo Nordisk Bagsvaerd" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Novo Nordisk Bagsvaerd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 4691]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novo nordisk Saudi trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVO NORDISK
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B02BD04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Refixia&reg; is<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_b1f2d8c6-79b1-42b6-b300-7a310548389e \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>Refixia contains the active substance nonacog beta pegol. It is a long-acting version of factor IX. Factor IX is a protein naturally found in the blood that helps to stop bleeding.<!--[if supportFields]><span
style='font-weight:normal'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_cd4192b6-6d1c-4102-aa9b-d1ba14976281 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-weight:normal'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>What Refixia&reg; is used for<!--[if supportFields]><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_34db68cc-775a-4da5-ac92-a8fa56515330 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>Refixia is used to treat and prevent bleeding in all age groups of patients with haemophilia B (inborn factor IX deficiency).</p><p>&nbsp;</p><p>In patients with haemophilia B, factor IX is missing or does not work properly. Refixia replaces this faulty or missing factor IX and helps blood to form clots at the site of bleeding.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Refixia&reg;<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_d216218f-24ce-4035-a45e-9db37a17783b \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to the active substance or any of the other ingredients of this medicine (listed in section 6).<!--[if supportFields]><span
style='font-weight:normal'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_3f75c2c4-7ed5-4616-901c-9ef976f3f2f8 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-weight:normal'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to hamster proteins.<!--[if supportFields]><span
style='font-weight:normal'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_461214ee-ac88-42ed-b1d0-47227f035b21 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-weight:normal'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>If you are not sure if either of the above applies to you, talk to your doctor before using this medicine.</p><p>&nbsp;</p><p><!--[if supportFields]><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>DOCVARIABLE
vault_nd_247496d9-a27c-4bb5-b1fb-a49e42cb20a2 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]-->Warnings and precautions<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_8f135f57-9195-4c9c-8259-58ee62081dd3 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><strong>Traceability </strong></p><p>It is important to keep a record of the batch number of your Refixia. So, every time you get a new package of Refixia, note down the date and the batch number (which is on the packaging after Lot) and keep this information in a safe place.<!--[if supportFields]><span
style='mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
color:black;font-weight:normal'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_ace78118-d04e-427c-9cdc-31dcb4a1e407 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
color:black;font-weight:normal'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><strong>Allergic reactions and development of inhibitors</strong></p><p>There is a rare risk that you may experience a sudden and severe allergic reaction (e.g. anaphylactic reaction) to Refixia&reg;. Stop the injection and contact your doctor or an emergency unit immediately if you have signs of an allergic reaction such as rash, hives, weals, itching of large areas of skin, redness and/or swelling of lips, tongue, face or hands, difficulty in swallowing or breathing, shortness of breath, wheezing, tightness of the chest, pale and cold skin, fast heartbeat, and/or dizziness.</p><p>&nbsp;</p><p>Your doctor may need to treat you promptly for these reactions. Your doctor may also carry out a blood test to check if you have developed factor IX inhibitors (neutralising antibodies) against your medicine, as inhibitors may develop together with allergic reactions. If you have such inhibitors, you may have a higher risk of sudden and severe allergic reactions (e.g. anaphylactic reaction) during future treatment with factor IX.</p><p>&nbsp;</p><p>Because of the risk of allergic reactions with factor IX, your initial treatment with Refixia&reg; should be given in a medical clinic or in the presence of health care professionals where proper medical care for allergic reactions can be provided if needed.</p><p>&nbsp;</p><p>Talk to your doctor immediately if your bleeding does not stop as expected or if you have to significantly increase the amount of Refixia you need to stop a bleed. Your doctor will do a blood test to check if you have developed inhibitors (neutralising antibodies) against Refixia. The risk for developing inhibitors is highest in people who have have not been treated with factor IX medicines before, typically small children.</p><p>&nbsp;</p><p><strong>Blood clots </strong></p><p>Tell your doctor, if any of the following apply to you as there is an increased risk of blood clots during treatment with Refixia:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have recently had surgery</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you suffer from other serious illness e.g. liver disease, heart disease, or cancer</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have risk factors for heart disease e.g high blood pressure, obesity, or smoking.</p><p>&nbsp;</p><p><strong>Kidney disorder (nephrotic syndrome) </strong></p><p>There is a rare risk of developing a specific kidney disorder called &ldquo;nephrotic syndrome&rdquo; following high doses of factor IX in haemophilia B patients with factor IX inhibitors and a history of allergic reactions.</p><p>&nbsp;</p><p><strong>Catheter-related problems </strong></p><p>If you have a central venous access device (CVAD), you may develop infections or blood clots at the site of the catheter.</p><p>&nbsp;</p><p>Other medicines and Refixia&reg;<!--[if supportFields]><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_45ecf567-2e91-47ab-966e-fa54cb50e936
\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines.<!--[if supportFields]><span
style='font-weight:normal'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_d189ec68-a1c0-418c-9bf2-76f69a01df1a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-weight:normal'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>Pregnancy and breast-feeding<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_a0bf53e4-f0c0-4805-bd49-b8c6c98c38f8 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using Refixia.</p><p>&nbsp;</p><p><!--[if supportFields]><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>DOCVARIABLE
vault_nd_2737df29-76ee-4920-aeb8-b16d494757b4 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>&nbsp;</p><p>Driving and using machines<!--[if supportFields]><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_8e7c3a55-f8bb-48fc-b585-9a961854329c \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>Refixia&reg; has no influence on the ability to drive and use machines.</p><p>&nbsp;</p><p><strong>Refixia&reg; contains sodium</strong></p><p>This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially &ldquo;sodium-free&rdquo;. In case of treatment with multiple vials, the total sodium content should be taken into consideration.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Treatment with Refixia will be started by a doctor who is experienced in the care of patients with haemophilia B. Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure about how to use Refixia.</p><p>&nbsp;</p><p>Your doctor will calculate the right dose for you. The dose will depend on your weight and what the medicine is being used for.</p><p>&nbsp;</p><p><strong>Prevention of bleeding </strong></p><p>The usual dose of Refixia is 40 international units (IU) per kg of body weight. This is given as one injection every week. Your doctor may choose another dose or change how often the injections should be given, based on your need.</p><p>&nbsp;</p><p><strong>Treatment of bleeding </strong></p><p>The usual dose of Refixia is 40 international units (IU) per kg of body weight. Depending on the location and the severity of bleeding you may need a higher dose (80 IU per kg) or extra injections. Discuss with your doctor the dose and number of injections you need.</p><p>&nbsp;</p><p><strong>Use in children and adolescents </strong></p><p>Refixia can be used in children and adolescents of all ages. The dose in children and adolescents is also calculated according to body weight and is the same dose as for adults.</p><p>&nbsp;</p><p><strong>How Refixia is given </strong></p><p>Refixia is available as powder and solvent that is made up into a solution (reconstitution) and given as an injection into a vein. See &ldquo;Instructions on how to use Refixia&rdquo; for more information.</p><p>&nbsp;</p><p><strong>If you use more Refixia than you should </strong></p><p>If you use more Refixia than you should, contact your doctor.</p><p>&nbsp;</p><p>If you have to significantly increase the amount of Refixia you need to stop a bleed, talk to your doctor immediately. For further information, see section 2 &ldquo;Allergic reactions and development of inhibitors&rdquo;.</p><p>&nbsp;</p><p><strong>If you forget to use Refixia </strong></p><p>If you forget a dose, inject the missed dose as soon as you remember. Do not inject a double dose to make up for a forgotten dose. If you are in doubt contact your doctor.</p><p>&nbsp;</p><p><strong>If you stop using Refixia </strong></p><p>If you stop using Refixia you may no longer be protected against bleeding or a current bleed may not stop. Do not stop using Refixia without talking to your doctor.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Allergic reactions (hypersensitivity) may occur when using this medicine.</p><p>&nbsp;</p><p>If sudden and severe allergic reactions (e.g., anaphylactic reactions) occur, the injection must be stopped</p><p>immediately. You must immediately contact your doctor or an emergency department if you experience</p><p>early signs of an allergic reaction, such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty swallowing or breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath or wheezing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest tightness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness and/or swelling of the lips, tongue, face or hands</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash, hives, weals, or itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pale and cold skin, fast heartbeat and/or dizziness (low blood pressure)</p><p>&nbsp;</p><p>For children not previously treated with factor IX medicines, inhibitors (see section 2) may form commonly (up to 1 in 10 patients). If this happens, the medicine may stop working properly and your child may experience persistent bleeding. If this happens, you should contact your doctor immediately.</p><p>&nbsp;</p><p><strong>The following side effects have been observed with Refixia&reg;</strong><strong>:</strong></p><p>&nbsp;</p><p><strong>Common side effects </strong>(may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions (hypersensitivity). This may become severe and could be life-threatening (anaphylactic reactions)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching (pruritus)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin reactions at the site of injection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling very tired</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children not previously treated with factor IX medicines: neutralising antibodies (inhibitors), anaphylactic reactions.</p><p>&nbsp;</p><p><strong>Uncommon side effects </strong>(may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart palpitations</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hot flush.</p><p>&nbsp;</p><p>Reporting of side effects<!--[if supportFields]><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_1f5cf5a8-55e1-4222-b3a1-6a4565834cdb \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.<!--[if supportFields]><span
lang=EN-GB style='font-size:10.5pt;mso-bidi-font-size:11.0pt;mso-ansi-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_bcc76739-99a8-44a5-9b52-bbed9c84a561 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:10.5pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><strong><u>Please report adverse drug events to:&nbsp;&nbsp;</u></strong></p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p>The National Pharmacovigilance Centre (NPC):</p><p>Fax: +966-11-205-7662</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use Refixia after the expiry date which is stated after &ldquo;EXP&rdquo; on the carton and on the vial and the pre-filled syringe labels. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in a refrigerator (2 &deg;C &ndash; 8 &deg;C). Do not freeze. Keep the vial in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>&nbsp;</p><p>Refixia may be taken out of the refrigerator for a maximum period of 1 year and stored at room temperature (up to 30 &deg;C). Please record on the carton the date Refixia is removed from the refrigerator and placed at room temperature. This new expiry date should never exceed the one initially mentioned on the outer carton. If the medicine has not been used before the new expiry date, it should be disposed of. After storage at room temperature the medicine must not be put back in the</p><p>refrigerator.</p><p>&nbsp;</p><p>Use the injection immediately after making up the solution (reconstitution). If it cannot be used immediately, use within 24 hours if stored in a refrigerator at 2 &deg;C &ndash; 8 &deg;C or within 4 hours if stored out of the refrigerator at a maximum temperature of 30 &deg;C.</p><p>&nbsp;</p><p>The powder in the vial appears as a white to off-white powder. Do not use the powder if the colour has changed.</p><p>&nbsp;</p><p>The reconstituted solution will be clear and colourless to slightly yellow. Do not use the reconstituted solution if you notice any particles or discolouration.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Refixia&reg; contains</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is nonacog beta pegol (pegylated human coagulation factor IX (rDNA)). Each vial of Refixia contains nominally 500 IU, 1 000 IU or 2 000 IU nonacog beta pegol corresponding to approximately 125 IU/ml, 250 IU/ml or 500 IU/ml respectively after reconstitution with histidine solvent.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients in the powder are sodium chloride, histidine, sucrose, polysorbate 80, mannitol, sodium hydroxide and hydrochloric acid. See section 2 &ldquo;Refixia contains sodium&rdquo;.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The ingredients in the sterilised solvent are histidine, water for injections, sodium hydroxide and hydrochloric acid.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Refixia looks like and contents of the pack 
•	Refixia is provided as a powder and solvent for solution for injection (500 IU, 1 000 IU or 2 000 IU powder in a vial and 4 ml solvent in a pre-filled syringe, a plunger rod with a vial adapter – pack size of 1). 
•	The powder is white to off-white and the solvent is clear and colourless.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Novo Nordisk A/S</p><p>Novo All&eacute;</p><p>DK-2880 Bagsv&aelig;rd, Denmark</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Nov/2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو دواء ريفكسيا</strong><strong><sup>&trade;</sup></strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><sup><span dir=LTR style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-begin'></span> DOCVARIABLE
VAULT_ND_f5df702e-bcdc-4071-9c13-5effd32aa690 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></sup></b><![endif]--><strong><sup>&nbsp;</sup></strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><sup><span dir=LTR style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-end'></span></span></sup></b><![endif]--></p><p dir="RTL">يحتوي ريفكسيا<sup>&trade;</sup> على المادة الفعالة &rlm;‫نوناكوج بيتا بيجول. وهو إصدار طويل المفعول من العامل التاسع. العامل التاسع عبارة عن بروتين موجود طبيعيًا في الدم والذي يساعد على وقف النزف.<!--[if supportFields]><span
dir=LTR><span style='mso-element:field-begin'></span> DOCVARIABLE
VAULT_ND_ef1f71fc-81f8-42fb-8580-5672e0801b73 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span dir=LTR><span
style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>دواعي استعمال ريفكسيا</strong><strong><sup>&trade;</sup></strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><sup><span dir=LTR style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-begin'></span> DOCVARIABLE
VAULT_ND_97b2a501-72ed-4d61-8a2c-a519e96e44ca \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></sup></b><![endif]--><strong><sup>&nbsp;</sup></strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><sup><span dir=LTR style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-end'></span></span></sup></b><![endif]--></p><p dir="RTL">يتم استخدام دواء ريفكسيا<sup>&trade;</sup> لعلاج ومنع النزيف الذي يحدث في جميع الفئات العمرية لمرضى الهيموفيليا ب (نقص وراثي في عامل التخثر التاسع).<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_a059ab47-a92b-4091-90e6-82e69982768f \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL">يعاني مرضى &quot;الهيموفيليا ب&quot; من عدم وجود العامل التاسع لتخثر الدم أو من عدم أدائه لوظائفه كما ينبغي. يحل دواء ريفكسيا<sup>&trade;</sup> محل هذا &quot;العامل التاسع&quot; غير الموجود أو الذي به خلل، ويساعد الدم على تكوين تخثرات في موضع النزف.<!--[if supportFields]><span lang=AR-SA
style='mso-ansi-language:EN-GB;mso-fareast-language:ZH-CN'><span
style='mso-element:field-begin'></span> </span><span lang=EN-GB dir=LTR
style='mso-ansi-language:EN-GB;mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span lang=EN-GB style='mso-ansi-language:
EN-GB;mso-fareast-language:ZH-CN'><span dir=RTL></span><span dir=RTL></span> </span><span
lang=EN-GB dir=LTR style='mso-ansi-language:EN-GB;mso-fareast-language:ZH-CN'>VAULT_ND_0e8558f9-8248-4026-b7ac-aa20d8c7f035
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
lang=EN-GB style='mso-ansi-language:EN-GB;mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span lang=AR-SA style='mso-ansi-language:
EN-GB;mso-fareast-language:ZH-CN'><span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استعمال ريفكسيا</strong><strong><sup>&trade;</sup></strong><strong>:</strong><!--[if supportFields]><b style='mso-ansi-font-weight:
normal'><span lang=AR-SA style='mso-fareast-language:ZH-CN'><span
style='mso-element:field-begin'></span> </span></b><span dir=LTR
style='mso-fareast-language:ZH-CN;mso-bidi-font-weight:bold'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
style='mso-fareast-language:ZH-CN'><span dir=RTL></span><span dir=RTL></span> </span></b><span
dir=LTR style='mso-fareast-language:ZH-CN;mso-bidi-font-weight:bold'>VAULT_ND_bffa522d-0109-46c6-a2b3-4a68001866c2
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الحساسية للمادة الفعالة أو لأي من المكونات الأخرى التي تدخل في تركيب هذا الدواء (الواردة في القسم 6).<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_dc1dbba9-875b-40fb-a54a-201961484507 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه بروتينات الجرذ الأرنبي.<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_4b93a9cb-ed85-4d39-8eeb-d0fb39163c7c \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت غير متأكد مما إذا كانت أي من الأمور الواردة أعلاه تنطبق عليك، فاستشر طبيبك قبل استعمال هذا الدواء.<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_faf2fc03-e549-44ef-b2d6-5e473e948e6b \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong><!--[if supportFields]><b style='mso-ansi-font-weight:
normal'><span lang=AR-SA style='mso-fareast-language:ZH-CN'><span
style='mso-element:field-begin'></span> </span></b><span dir=LTR
style='mso-fareast-language:ZH-CN;mso-bidi-font-weight:bold'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
style='mso-fareast-language:ZH-CN'><span dir=RTL></span><span dir=RTL></span> </span></b><span
dir=LTR style='mso-fareast-language:ZH-CN;mso-bidi-font-weight:bold'>VAULT_ND_1723abcc-48a4-4e57-ac23-982793b81d39
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL"><strong>قابلية التتبع</strong><!--[if supportFields]><b><span
lang=AR-SA style='mso-ansi-language:EN-GB;mso-fareast-language:ZH-CN'><span
style='mso-element:field-begin'></span> </span></b><b><span lang=EN-GB dir=LTR
style='mso-ansi-language:EN-GB;mso-fareast-language:ZH-CN'>DOCVARIABLE</span></b><span
dir=RTL></span><span dir=RTL></span><b><span lang=EN-GB style='mso-ansi-language:
EN-GB;mso-fareast-language:ZH-CN'><span dir=RTL></span><span dir=RTL></span> </span></b><b><span
lang=EN-GB dir=LTR style='mso-ansi-language:EN-GB;mso-fareast-language:ZH-CN'>VAULT_ND_5d6cfe86-3ef1-4df5-b2b5-e417d0073958
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
lang=EN-GB style='mso-ansi-language:EN-GB;mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span></b><b><span lang=AR-SA
style='mso-ansi-language:EN-GB;mso-fareast-language:ZH-CN'><span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='mso-ansi-language:EN-GB;mso-fareast-language:ZH-CN'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">من المهم الاحتفاظ بسجل لرقم دفعة عقار ريفكسيا&trade;. لذلك، في كل مرة تحصل فيها على عبوة جديدة من ريفكسيا&trade;، دوّن التاريخ ورقم الدفعة (الموجود على العبوة بعد التشغيلة) واحتفظ بهذه المعلومات في مكان آمن.</p><p dir="RTL"><strong><em>&nbsp;</em></strong></p><p dir="RTL"><strong>تفاعلات الحساسية وتكوّن المثبطات</strong><!--[if supportFields]><b style='mso-ansi-font-weight:
normal'><span lang=AR-SA style='mso-fareast-language:ZH-CN;mso-ansi-font-style:
italic'><span style='mso-element:field-begin'></span> </span></b><i
style='mso-bidi-font-style:normal'><span dir=LTR style='mso-fareast-language:
ZH-CN;mso-bidi-font-weight:bold'>DOCVARIABLE</span></i><span dir=RTL></span><span
dir=RTL></span><b style='mso-ansi-font-weight:normal'><span style='mso-fareast-language:
ZH-CN;mso-ansi-font-style:italic'><span dir=RTL></span><span dir=RTL></span> </span></b><i
style='mso-bidi-font-style:normal'><span dir=LTR style='mso-fareast-language:
ZH-CN;mso-bidi-font-weight:bold'>VAULT_ND_cc226cf9-cccd-4200-81aa-4baf3f7d9527
\* MERGEFORMAT</span></i><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span style='mso-fareast-language:ZH-CN;
mso-ansi-font-style:italic'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-fareast-language:
ZH-CN;mso-ansi-font-style:italic'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">هناك احتمالية نادرة للتعرض لتفاعل حساسية مفاجئ وشديد (مثل، تفاعل تأقي) نتيجة لاستعمال ريفكسيا<sup>&trade;</sup>. أوقف الحقن واتصل بطبيبك أو بوحدة الطوارئ على الفور إذا كانت لديك علامات حدوث تفاعل حساسية، مثل الطفح الجلدي، الشرى، الانتبار، الحكة في مساحات كبيرة من الجلد، احمرار و/أو تورم الشفاه، أو اللسان، أو الوجه أو اليدين، صعوبة في البلع أو التنفس، ضيق في التنفس، أزيز، ضيق في الصدر، شحوب وبرودة في الجلد، سرعة ضربات القلب، و/أو الدوار.<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_6abfa0a4-95cc-4a80-8678-2a34fcb46258 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يحتاج طبيبك إلى علاجك على الفور من هذه التفاعلات. قد يجري طبيبك أيضًا اختبارًا للدم للتحقق مما إذا كان قد تكونت لديك مثبطات العامل التاسع (الأجسام المضادة المبطلة للمفعول) ضد الدواء الخاص بك، حيث قد تتكوّن المثبطات مع تفاعلات الحساسية. إذا كانت لديك مثل هذه المثبطات، فقد تكون عرضة لخطر أعلى من حدوث تفاعلات حساسية مفاجئة وشديدة (على سبيل المثال، تفاعل تأقي) أثناء العلاج في المستقبل بالعامل التاسع.<!--[if supportFields]><span lang=AR-SA
style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_05aacb93-2327-4090-97e9-de88fd76aaa3 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL">بسبب خطر تفاعلات الحساسية مع العلاج بالعامل التاسع، يجب أن يتم إعطاء علاجك الأولي من ريفكسيا<sup>&trade;</sup> في عيادة طبية أو في وجود متخصصي الرعاية الصحية، بحيث يمكن توفير الرعاية الطبية المناسبة في حالة حدوث تفاعلات حساسية، إذا لزم الأمر.<!--[if supportFields]><span lang=AR-SA
style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_2c048609-7501-4266-9995-93de72e09b3a \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث إلى طبيبك على الفور إذا كان النزيف لديك لا يتوقف كما هو متوقع أو إذا كنت في حاجة إلى زيادة الكمية من عقار ريفكسيا<sup>&trade;</sup> التي تحتاجها بشكل كبير من أجل إيقاف النزيف. سيقوم طبيبك بإجراء اختبار للدم للتحقق مما إذا كان قد تكونت لديك مثبطات (الأجسام المضادة المبطلة للمفعول) ضد ريفكسيا<sup>&trade;</sup>. تكون مخاطر تكوّن المثبطات في أعلى مستوىً لدى الأشخاص الذين لم يعالجوا بأدوية العامل التاسع من قبل، وبالمثل بالنسبة للأطفال الصغار.<!--[if supportFields]><span lang=AR-SA style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-begin'></span> </span><span dir=LTR
style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span dir=RTL></span><span
dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:ZH-CN'>VAULT_ND_d0880f1c-e853-440c-8683-d287e18fa85b
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-fareast-language:ZH-CN'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجلطات الدموية</strong><!--[if supportFields]><b style='mso-ansi-font-weight:normal'><span
lang=AR-SA style='mso-fareast-language:ZH-CN;mso-ansi-font-style:italic'><span
style='mso-element:field-begin'></span> </span></b><i style='mso-bidi-font-style:
normal'><span dir=LTR style='mso-fareast-language:ZH-CN;mso-bidi-font-weight:
bold'>DOCVARIABLE</span></i><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span style='mso-fareast-language:ZH-CN;
mso-ansi-font-style:italic'><span dir=RTL></span><span dir=RTL></span> </span></b><i
style='mso-bidi-font-style:normal'><span dir=LTR style='mso-fareast-language:
ZH-CN;mso-bidi-font-weight:bold'>VAULT_ND_f5a5b440-8677-456a-869b-36efc5adc719
\* MERGEFORMAT</span></i><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span style='mso-fareast-language:ZH-CN;
mso-ansi-font-style:italic'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-fareast-language:
ZH-CN;mso-ansi-font-style:italic'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">أخبر طبيبك إذا كان أي مما يلي ينطبق عليك، لأن هناك احتمالية متزايدة لخطر الإصابة بجلطات الدم أثناء العلاج باستخدام ريفكسيا<sup>&trade;</sup>:<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_eb6addd1-5019-4808-aaf2-a1192ce07a6e \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت قد خضعت لأية جراحة مؤخراً</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من مرض خطير آخر مثل أمراض الكبد، أو أمراض القلب، أو السرطان</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك عوامل خطر للإصابة بأمراض القلب، مثل ارتفاع ضغط الدم، أو السمنة، أو التدخين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اضطراب كلوي (متلازمة كلوية)</strong><!--[if supportFields]><b style='mso-ansi-font-weight:
normal'><span lang=AR-SA style='mso-fareast-language:ZH-CN;mso-ansi-font-style:
italic'><span style='mso-element:field-begin'></span> </span></b><i
style='mso-bidi-font-style:normal'><span dir=LTR style='mso-fareast-language:
ZH-CN;mso-bidi-font-weight:bold'>DOCVARIABLE</span></i><span dir=RTL></span><span
dir=RTL></span><b style='mso-ansi-font-weight:normal'><span style='mso-fareast-language:
ZH-CN;mso-ansi-font-style:italic'><span dir=RTL></span><span dir=RTL></span> </span></b><i
style='mso-bidi-font-style:normal'><span dir=LTR style='mso-fareast-language:
ZH-CN;mso-bidi-font-weight:bold'>VAULT_ND_c34397d5-8a6b-4752-bef3-9cc29cb80abe
\* MERGEFORMAT</span></i><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span style='mso-fareast-language:ZH-CN;
mso-ansi-font-style:italic'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-fareast-language:
ZH-CN;mso-ansi-font-style:italic'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">هناك احتمالية لخطر نادر للإصابة باضطراب كلوي معين يسمى &quot;المتلازمة الكلوية&quot; بعد العلاج بجرعات كبيرة من العامل التاسع في مرضى &quot;الهيموفيليا ب&quot; الذين يعالجون بمثبطات العامل التاسع وتاريخ من الإصابة بتفاعلات الحساسية.<!--[if supportFields]><span lang=AR-SA
style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_a13f8e9f-b51b-4236-b58d-f1c8c0bf5341 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مشاكل تتعلق بالقسطرة</strong><!--[if supportFields]><b style='mso-ansi-font-weight:
normal'><span lang=AR-SA style='mso-fareast-language:ZH-CN;mso-ansi-font-style:
italic'><span style='mso-element:field-begin'></span> </span></b><i
style='mso-bidi-font-style:normal'><span dir=LTR style='mso-fareast-language:
ZH-CN;mso-bidi-font-weight:bold'>DOCVARIABLE</span></i><span dir=RTL></span><span
dir=RTL></span><b style='mso-ansi-font-weight:normal'><span style='mso-fareast-language:
ZH-CN;mso-ansi-font-style:italic'><span dir=RTL></span><span dir=RTL></span> </span></b><i
style='mso-bidi-font-style:normal'><span dir=LTR style='mso-fareast-language:
ZH-CN;mso-bidi-font-weight:bold'>VAULT_ND_9f6987cf-a0c0-4ad9-b852-b77a8c2d18d7
\* MERGEFORMAT</span></i><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span style='mso-fareast-language:ZH-CN;
mso-ansi-font-style:italic'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-fareast-language:
ZH-CN;mso-ansi-font-style:italic'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">إذا كان لديك جهاز وصول مركزي وريدي (CVAD)، فقد تصاب بالتهابات أو جلطات دموية في موضع القسطرة.<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_96b230c5-8353-475d-a5f3-09651f51240c \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وريفكسيا</strong><strong><sup>&trade;</sup></strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><sup><span dir=LTR style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-begin'></span> DOCVARIABLE
VAULT_ND_742f3dd4-86f8-405a-8b2c-42fc3721ec64 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></sup></b><![endif]--><strong><sup>&nbsp;</sup></strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><sup><span dir=LTR style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-end'></span></span></sup></b><![endif]--></p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أدوية أخرى، أو قد تناولت أية أدوية أخرى مؤخرًا أو قد تتناول أدوية أخرى.<!--[if supportFields]><span lang=AR-SA
style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_9a19b3ea-ca60-493c-85ac-497b4f924962 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-begin'></span> </span></b><span dir=LTR
style='mso-fareast-language:ZH-CN;mso-bidi-font-weight:bold'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
style='mso-fareast-language:ZH-CN'><span dir=RTL></span><span dir=RTL></span> </span></b><span
dir=LTR style='mso-fareast-language:ZH-CN;mso-bidi-font-weight:bold'>VAULT_ND_d6b0d47d-1e7a-428d-a145-81cb30d68442
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">في حالة الحمل أو الرضاعة الطبيعية، أو إذا كنتِ تظنين أنكِ حاملا أو إذا كنتِ تنوين الحمل، فاستشيري طبيبك قبل استعمال ريفكسيا<sup>&trade;</sup>.<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_9faaf9b0-2e35-4065-8a81-422e526d7ffe \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-begin'></span> </span></b><span dir=LTR
style='mso-fareast-language:ZH-CN;mso-bidi-font-weight:bold'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
style='mso-fareast-language:ZH-CN'><span dir=RTL></span><span dir=RTL></span> </span></b><span
dir=LTR style='mso-fareast-language:ZH-CN;mso-bidi-font-weight:bold'>VAULT_ND_64422764-65e7-410a-9bd3-8a2818f414bf
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">لا يوجد تأثير لدواء ريفكسيا<sup>&trade;</sup> على القدرة على القيادة واستخدام الآلات.<!--[if supportFields]><span lang=AR-SA
style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_fc9aa7e0-929c-4379-a84a-b7e074d7f166 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي دواء ريفكسيا</strong><strong><sup>&trade;</sup></strong><strong> على صوديوم</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-begin'></span> </span></b><span dir=LTR
style='mso-fareast-language:ZH-CN;mso-bidi-font-weight:bold'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
style='mso-fareast-language:ZH-CN'><span dir=RTL></span><span dir=RTL></span> </span></b><span
dir=LTR style='mso-fareast-language:ZH-CN;mso-bidi-font-weight:bold'>VAULT_ND_f7311cbd-1525-4bf6-b86f-bcd8afdba590
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول صوديوم (23 ملغ) لكل قنينة، &rlm;‫وهذا يعني أنه &quot;خالٍ من الصوديوم&quot; بشكل أساسي. في حالة العلاج بقنينات متعددة، ينبغي مراعاة المحتوى الكلي للصوديوم.<!--[if supportFields]><span dir=LTR><span
style='mso-element:field-begin'></span> DOCVARIABLE
VAULT_ND_22aafc26-7302-4cd0-b1c4-b629321176b4 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب أن يبدأ العلاج بدواء ريفكسيا<sup>&trade;</sup> من قِبل طبيب ذي خبرة في رعاية مرضى &quot;الهيموفيليا ب&quot;. التزم دائمًا باستخدام هذا الدواء بالطريقة التي يصفها لك طبيبك بالضبط. كما يجب مراجعة الطبيب أو الصيدلاني إذا لم تكن متأكدًا من كيفية استعمال ريفكسيا<sup>&trade;</sup>.<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_39fdcd84-8715-40c9-b140-007ff5d04207 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL">سوف يقوم الطبيب باحتساب الجرعة المناسبة لك. وستعتمد الجرعة على وزنك ودواعي استعمال الدواء.<!--[if supportFields]><span lang=AR-SA
style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_d9c54a79-c292-40b4-a8dd-1797d7ed5001 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>منع النزيف</strong></p><p dir="RTL">تبلغ الجرعة المعتادة من دواء ريفكسيا<sup>&trade;</sup> مقدار 40 وحدة دولية (IU) لكل كغم من وزن الجسم. ويتم إعطاؤه على هيئة حقنة واحدة كل أسبوع. قد يختار طبيبك جرعة أخرى أو تغيير معدل آخر لتكرار الحقن، بناءً على حاجتك.<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_c8f7e72b-5664-4a56-b35b-489e2aa1563f \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>علاج النزيف</strong><!--[if supportFields]><b><span lang=AR-SA
style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span></b><b><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span></b><b><span dir=LTR
style='mso-fareast-language:ZH-CN'>VAULT_ND_a3fdf3a8-14d7-421e-9593-78fb552f22f8
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='mso-fareast-language:ZH-CN'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">تبلغ الجرعة المعتادة من دواء ريفكسيا<sup>&trade;</sup> مقدار 40 وحدة دولية (IU) لكل كغم من وزن الجسم. اعتمادًا على مكان وشدة النزف، قد تحتاج إلى جرعة أعلى (80 وحدة دولية لكل كغم) أو حقن إضافية. ناقش مع طبيبك الجرعة وعدد الحقن التي تحتاجها.<!--[if supportFields]><span lang=AR-SA
style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_3097b2cb-2952-49fe-8bc6-4aa279d1c854 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستعمال للأطفال والمراهقين</strong><!--[if supportFields]><b><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span></b><b><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span></b><b><span dir=LTR
style='mso-fareast-language:ZH-CN'>VAULT_ND_07ba619e-f071-4ab7-a841-7bf5a03698bb
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='mso-fareast-language:ZH-CN'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">يمكن استعمال ريفكسيا<sup>&trade;</sup> مع الأطفال والمراهقين من جميع الأعمار. يتم احتساب الجرعة في الأطفال والمراهقين أيضًا حسب وزن الجسم وهي نفس الجرعة بالنسبة للبالغين.<!--[if supportFields]><span lang=AR-SA
style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_b43c1174-9fac-4e1f-8dfe-b20ed137564b \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية إعطاء دواء ريفكسيا</strong><strong><sup>&trade;</sup></strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><sup><span dir=LTR style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-begin'></span> DOCVARIABLE
VAULT_ND_6d8b8e49-e810-4364-aa70-63c1677a8317 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></sup></b><![endif]--><strong><sup>&nbsp;</sup></strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><sup><span dir=LTR style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-end'></span></span></sup></b><![endif]--></p><p dir="RTL">دواء ريفكسيا<sup>&trade;</sup> متوفر كمسحوق ومذيب يتم تكوينه في محلول (التحضير) ويؤخذ دواء ريفكسيا<sup>&trade;</sup> كحقنة في الوريد. انظر تعليمات عن كيفية استعمال ريفكسيا<em><sup>&trade;</sup></em> للحصول على مزيد من المعلومات.<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_e13a7b42-ebc7-4c99-a5ab-7bb2cb34fdbc \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة تناول جرعة زائدة من ريفكسيا</strong><strong><sup>&trade;</sup></strong><strong> عن الجرعة الموصوفة</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-begin'></span> </span></b><span dir=LTR
style='mso-fareast-language:ZH-CN;mso-bidi-font-weight:bold'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
style='mso-fareast-language:ZH-CN'><span dir=RTL></span><span dir=RTL></span> </span></b><span
dir=LTR style='mso-fareast-language:ZH-CN;mso-bidi-font-weight:bold'>VAULT_ND_a45900b5-d810-47b7-b418-c71200c71c24
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">في حالة تناول جرعة زائدة من ريفكسيا<sup>&trade;</sup> عن الجرعة الموصوفة، اتصل بالطبيب.<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_e85899f8-de93-4aba-8b4f-b48b7cbd7d90 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت في حاجة إلى زيادة الكمية من عقار ريفكسيا<sup>&trade;</sup> التي تحتاجها لإيقاف حالة من النزف، فتحدث إلى طبيبك على الفور. لمزيد من المعلومات، انظر القسم 2، &quot;&rlm;‫تفاعلات الحساسية وتكوّن المثبطات<em>&quot;</em>.<!--[if supportFields]><span
dir=LTR><span style='mso-element:field-begin'></span> DOCVARIABLE
VAULT_ND_6b3a48f2-784e-4ecf-8566-d704f624c80d \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span dir=LTR><span
style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة نسيان جرعة ريفكسيا</strong><strong><sup>&trade;</sup></strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><sup><span dir=LTR style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-begin'></span> DOCVARIABLE
VAULT_ND_cfb6cb04-b031-4946-a3ba-8b5ce5003f17 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></sup></b><![endif]--><strong><sup>&nbsp;</sup></strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><sup><span dir=LTR style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-end'></span></span></sup></b><![endif]--></p><p dir="RTL">في حالة نسيان جرعة، فاحقن الجرعة الفائتة في أسرع وقت بمجرد تذكرها. لا تحقن جرعة مضاعفة لتعويض الجرعة التي فاتتك. يجب استشارة الطبيب في حالة الشك.<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_2ed31f19-ef16-49b0-80ea-6c8d1f22e887 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة التوقف عن استخدام دواء ريفكسيا</strong><strong><sup>&trade;</sup></strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><sup><span dir=LTR style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-begin'></span> DOCVARIABLE
VAULT_ND_373f59f2-7a5a-46a0-bf85-babe9dc9054f \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></sup></b><![endif]--><strong><sup>&nbsp;</sup></strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><sup><span dir=LTR style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-end'></span></span></sup></b><![endif]--></p><p dir="RTL">في حالة التوقف عن استخدام دواء ريفكسيا<sup>&trade;</sup>، فأنت لم تعد في حماية ضد حدوث نزيف أو قد لا يتوقف النزيف الحالي. لا تتوقف عن استعمال ريفكسيا<sup>&trade;</sup> دون استشارة الطبيب.<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_b7750908-9eb3-4b41-872c-1faf5152295a \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استعمال هذا الدواء، فاسأل الطبيب.<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_5b18251c-28e8-4097-b48e-7cac6a48765f \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية وإن كانت لا تحدث في جميع الأشخاص الذين يستخدمونه.<!--[if supportFields]><span lang=AR-SA
style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_65336b63-c6a9-44b2-833e-0d60dd366f01 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL">من المحتمل حدوث تفاعلات الحساسية مع هذا الدواء.<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_73293b61-be5f-4829-b0e1-e480ec0f23bb \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">في حالة حدوث تفاعل حساسية مفاجئ وشديد (مثل، تفاعلات تأقية)، يجب التوقف عن الحقن فورًا. يجب عليك الاتصال بالطبيب أو وحدة الطوارئ على الفور إذا كان لديك علامات مبكرة على وجود تفاعل حساسية شديد (رد فعل تحسسي) مثل:<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_656fd180-e8e3-4ad2-bc47-db4333aa5a82 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في البلع أو التنفس<!--[if supportFields]><span lang=AR-SA style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-begin'></span> </span><span dir=LTR
style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span dir=RTL></span><span
dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:ZH-CN'>VAULT_ND_86f70434-76d5-4589-b61b-d581d5fa7579
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-fareast-language:ZH-CN'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق النفس أو أزيز<!--[if supportFields]><span lang=AR-SA style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-begin'></span> </span><span dir=LTR
style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span dir=RTL></span><span
dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:ZH-CN'>VAULT_ND_ed2052c3-c276-454d-9492-0c110b4eafb2
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-fareast-language:ZH-CN'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في الصدر<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_3087c5c9-b377-47d6-94cd-3db1f8ab5241 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار و/أو تورم الشفاه، أو اللسان، أو الوجه أو اليدين<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_0a9c4372-12fb-46d8-9cec-2df5eceea4e4 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي، أو الشرى، أو الانتبار، أو الحكة<!--[if supportFields]><span lang=AR-SA
style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_6c5d8a5d-41bd-49aa-9399-c8b9f00a1f8b \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شحوب وبرودة في الجلد، سرعة ضربات القلب، و/أو الدوار (انخفاض ضغط الدم).<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_a441871c-c862-4944-969f-43f137efe651 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL">بالنسبة للأطفال الذين لم يتم علاجهم من قبل بأدوية العامل التاسع، قد تتشكّل المثبطات (انظر القسم 2) بشكل شائع (حتى 1 من كل 10 مرضى). وإذا حدث هذا، فقد يتوقف المفعول بشكل صحيح وقد يعاني طفلك من نزيف مستمر. وإذا حدث هذا، فيجب عليك الاتصال بطبيبك على الفور.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>لوحظت الآثار الجانبية التالية مع العلاج بريفكسيا</strong><strong><sup>&trade;</sup></strong><strong>:</strong><!--[if supportFields]><b style='mso-ansi-font-weight:
normal'><span lang=AR-SA style='mso-fareast-language:ZH-CN'><span
style='mso-element:field-begin'></span> </span></b><span dir=LTR
style='mso-fareast-language:ZH-CN;mso-bidi-font-weight:bold'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
style='mso-fareast-language:ZH-CN'><span dir=RTL></span><span dir=RTL></span> </span></b><span
dir=LTR style='mso-fareast-language:ZH-CN;mso-bidi-font-weight:bold'>VAULT_ND_aeed0e80-4ee4-43f6-937b-8cd6aa4d8001
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشائعة</strong> (قد تصيب حتى شخص واحد من بين 10 أشخاص)<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_833f4c03-338b-4b21-b9d9-3f69e517bbce \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية (فرط الحساسية). قد تصبح شديدة ويمكن أن تكون مهددة للحياة (تفاعلات تأقية)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة (حكاك)<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_6a5b6258-d7fa-4d51-8553-3404eb08f523 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلدية في موضع الحقن<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_cc628c58-0f29-4bbe-ba0f-0e96aa17e1ba \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالتوعك (غثيان)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإرهاق الشديد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشري</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأطفال الذين لم يعالجوا سابقًا بأدوية العامل التاسع: تحييد الأجسام المضادة (مثبطات)، تفاعلات تأقية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة </strong>(قد تصيب حتى شخص واحد من بين 100 أشخاص)<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_aef7e7f2-4b86-444d-91cb-b067e632eebd \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خفقان القلب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هبات ساخنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-begin'></span> </span></b><span dir=LTR
style='mso-fareast-language:ZH-CN;mso-bidi-font-weight:bold'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
style='mso-fareast-language:ZH-CN'><span dir=RTL></span><span dir=RTL></span> </span></b><span
dir=LTR style='mso-fareast-language:ZH-CN;mso-bidi-font-weight:bold'>VAULT_ND_f7b65df3-df62-414d-9dcf-16248908d125
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">في حالة إصابتك بأي آثار جانبية، استشر الطبيب أو الصيدلي أو الممرضة. يشمل هذا أية آثار جانبية محتملة غير واردة في هذه النشرة. من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>يُرجى الإبلاغ عن الآثار الجانبية للدواء إلى:</u></strong></p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p dir="RTL">المركز الوطني للتيقظ الدوائي (NPC):</p><p dir="RTL">فاكس: +966-11-205-7662</p><p dir="RTL">مركز اتصالات الهيئة العامة للغذاء والدواء: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن متناول ومرأى الأطفال.<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_054ef7d9-9f1a-4f3c-a321-abc912176148 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم دواء ريفكسيا<sup>&trade;</sup> بعد تاريخ انتهاء الصلاحية المدون بعد كلمة &quot;Expiry&quot; على العبوة الكرتونية وعلى القنينة وعلى ملصقات الحُقن المعبأة مسبقًا. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر المذكور.<!--[if supportFields]><span lang=AR-SA
style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>vault_nd_f500c8af-8805-4675-aa39-521754202cf8 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL">يُخزن في الثلاجة (في درجة حرارة 2-8 درجات مئوية) يُراعى عدم التجميد. تحفظ القنينة في العلبة الكرتونية الخارجية لحمايتها من الضوء.<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_256c36f6-f6a9-42b0-af78-ce565c4a1313 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL">يجوز إخراج ريفكسيا<sup>&trade;</sup> من الثلاجة لمدة أقصاها سنة واحدة وتخزينه في درجة حرارة الغرفة (حتى 30 درجة مئوية). يرجى التدوين على العبوة الكرتونية التاريخ الذي تم فيه إخراج ريفكسيا<sup>&trade;</sup> من الثلاجة ووضعه في درجة حرارة الغرفة. يجب ألا يتجاوز تاريخ انتهاء الصلاحية الجديد أبداً التاريخ المدون في الأصل على العبوة الكرتونية الخارجية. وإذا لم يتم استخدام الدواء قبل تاريخ انتهاء الصلاحية الجديد، يجب التخلص منه. بعد تخزينه في درجة حرارة الغرفة، يجب عدم إعادة الدواء إلى الثلاجة.<!--[if supportFields]><span lang=AR-SA style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-begin'></span> </span><span dir=LTR
style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span dir=RTL></span><span
dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:ZH-CN'>VAULT_ND_1de4c516-2af2-496c-837a-90b7f5d8f7db
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-fareast-language:ZH-CN'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL">استخدم الحقنة فور صنع المحلول (تحضيرها). وإذا تعذر استعمالها فورًا، يجب استعمالها خلال 24 ساعة إذا تم تخزينها في الثلاجة في درجة حرارة من 2 إلى 8 درجة مئوية، أو خلال 4 ساعات إذا تم تخزينها خارج الثلاجة في درجة حرارة لا تزيد عن 30 درجة مئوية.<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_300ec36a-d2ac-4d74-971c-268de10fa452 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL">يظهر المسحوق الموجود في القنينة كمسحوق أبيض إلى أبيض مائل للاصفرار. لا تستخدم المسحوق إذا تغير لونه.<!--[if supportFields]><span lang=AR-SA
style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_77b7e835-fab9-479c-abff-2991ed8398aa \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL">سوف يكون المحلول الذي تم تحضيره صافيًا أو عديم اللون إلى الأصفر قليلًا. لا تستخدم المحلول الذي تم تحضيره إذا لاحظت وجود جزيئيات داخله أو إذا تغير لونه.<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_18c6d5e7-964c-4956-9d31-7a049ef91478 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أية أدوية عبر مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي بشأن كيفية التخلص من الأدوية التي لم تعد تستعملها. ستساعد هذه التدابير على حماية البيئة.<!--[if supportFields]><span lang=AR-SA
style='mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> </span><span dir=LTR style='mso-fareast-language:
ZH-CN'>VAULT_ND_24066f1d-31aa-4f02-ad28-894e6e6dbd3e \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات ريفكسيا</strong><strong><sup>&trade;</sup></strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><sup><span dir=LTR style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-begin'></span> DOCVARIABLE
VAULT_ND_4ebb2565-440a-4bfc-a54a-b61d9a6e5f34 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></sup></b><![endif]--><strong><sup>&nbsp;</sup></strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><sup><span dir=LTR style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-end'></span></span></sup></b><![endif]--></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتمثل المادة الفعالة في &rlm;‫نوناكوج بيتا بيجول (عامل التخثر التاسع البشري المُبلمر (الحمض النووي المؤتلف)). تحتوي كل قنينة من ريفكسيا<sup>&trade;</sup> اسميًا على 500 وحدة دولية، أو 1000 وحدة دولية أو2000 وحدة دولية &rlm;‫نوناكوج بيتا بيجول، والتي تعادل حوالي 125 وحدة دولية/مل، أو 250 وحدة دولية/مل أو 500 وحدة دولية/مل على التوالي بعد التحضير بمذيبات الهيستدين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتمثل المكونات الأخرى الموجودة في المسحوق في كلوريد الصوديوم، وهيستيدين، وسكروز، وبوليسوربات 80، ومانيتول، وهيدروكسيد الصوديوم وحمض الهيدروكلوريك. انظر القسم 2 &quot;يحتوي ريفكسيا<strong><sup>&trade;</sup></strong> على الصوديوم&quot;<!--[if supportFields]><span
lang=AR-SA style='font-size:12.0pt;mso-ansi-font-size:11.0pt;mso-ansi-language:
EN-GB;mso-fareast-language:ZH-CN'><span style='mso-element:field-begin'></span>
</span><span lang=EN-GB dir=LTR style='mso-bidi-font-size:12.0pt;mso-ansi-language:
EN-GB;mso-fareast-language:ZH-CN'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span lang=EN-GB style='font-size:12.0pt;mso-ansi-font-size:
11.0pt;mso-ansi-language:EN-GB;mso-fareast-language:ZH-CN'><span dir=RTL></span><span
dir=RTL></span> </span><span lang=EN-GB dir=LTR style='mso-bidi-font-size:12.0pt;
mso-ansi-language:EN-GB;mso-fareast-language:ZH-CN'>VAULT_ND_ff4e931c-54c7-4d68-980f-317ddbd0a61f
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
lang=EN-GB style='font-size:12.0pt;mso-ansi-font-size:11.0pt;mso-ansi-language:
EN-GB;mso-fareast-language:ZH-CN'><span dir=RTL></span><span dir=RTL></span> </span><span
lang=AR-SA style='font-size:12.0pt;mso-ansi-font-size:11.0pt;mso-ansi-language:
EN-GB;mso-fareast-language:ZH-CN'><span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='font-size:12.0pt;mso-ansi-font-size:11.0pt;mso-ansi-language:
EN-GB;mso-fareast-language:ZH-CN'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وتتمثل المكونات الموجودة في المذيب المعقم في هيستيدين، وماء للحقن، وهيدروكسيد الصوديوم وحمض الهيدروكلوريك.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل ريفكسيا</strong><strong><sup>&trade;</sup></strong><strong> ومحتويات العبوة</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-begin'></span> </span></b><span dir=LTR
style='mso-fareast-language:ZH-CN;mso-bidi-font-weight:bold'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
style='mso-fareast-language:ZH-CN'><span dir=RTL></span><span dir=RTL></span> </span></b><span
dir=LTR style='mso-fareast-language:ZH-CN;mso-bidi-font-weight:bold'>VAULT_ND_e5e36d22-b281-4783-b467-cfd42b1516ba
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span style='mso-fareast-language:ZH-CN'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-fareast-language:
ZH-CN'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتوفر ريفكسيا<sup>&trade;</sup> على شكل مسحوق ومذيب لمحلول الحقن (مسحوق 500 وحدة دولية، 1000 وحدة دولية أو2000 وحدة دولية في قنينة و4 مل مذيب في محقنة معبأة مسبقًا، وذراع كبّاس مع مهايئ للقنينة - &rlm;‫يبلغ حجم العبوة قنينة واحدة).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المسحوق لونه أبيض إلى أبيض مائل للصفرة والمذيب صافٍ وعديم اللون.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">Novo Nordisk A/S</p><p dir="RTL">Novo All&eacute;</p><p dir="RTL">DK-2880 Bagsv&aelig;rd<strong>، الدنمارك</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نوفمبر/2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Refixia 500 IU powder and solvent for solution for injection
Refixia 1000 IU powder and solvent for solution for injection 
Refixia 2000 IU powder and solvent for solution for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Refixia 500 IU powder and solvent for solution for injection Each vial contains nominally 500 IU nonacog beta pegol*.
After reconstitution, 1 ml of Refixia contains approximately 125 IU nonacog beta pegol.

Refixia 1000 IU powder and solvent for solution for injection Each vial contains nominally 1000 IU nonacog beta pegol*.
After reconstitution, 1 ml of Refixia contains approximately 250 IU nonacog beta pegol.

Refixia 2000 IU powder and solvent for solution for injection Each vial contains nominally 2000 IU nonacog beta pegol*.
After reconstitution, 1 ml of Refixia contains approximately 500 IU nonacog beta pegol.

*recombinant human factor IX, produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology, covalently conjugated to a 40 kDa polyethylene-glycol (PEG).

The potency (International Units) is determined using the European Pharmacopeia one-stage clotting test. The specific activity of Refixia is approximately 144 IU/mg protein.

Refixia is a purified recombinant human factor IX (rFIX) with a 40 kDa polyethylene-glycol (PEG) selectively attached to specific N-linked glycans in the rFIX activation peptide. Upon activation of Refixia, the activation peptide including the 40 kDa polyethylene-glycol moiety is cleaved off, leaving the native activated factor IX molecule. The primary amino acid sequence of the rFIX in Refixia is identical to the Ala148 allelic form of human plasma-derived factor IX. No additives of human or animal origin are used in the cell culture, purification, conjugation, or formulation of Refixia.

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and solvent for solution for injection. 
The powder is white to off-white.
The solvent is clear and colourless. pH: 6.4.
Osmolality: 272 mOsmol/kg.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).</p><p>&nbsp;</p><p>Refixia can be used for all age groups.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment should be under the supervision of a physician experienced in the treatment of haemophilia.</p><p>&nbsp;</p><p><u>Treatment monitoring</u></p><p>Routine monitoring of factor IX activity levels with the goal of dose adjustment is generally not required. No dose adjustment was made in the clinical trial program. Mean trough levels of factor IX steady state &ge;15% were observed in all age groups, see section 5.2 for details.</p><p>&nbsp;</p><p>For modified long-acting factor preparations, the results of the one-step coagulation test are known to be highly dependent on the aPTT reagents used and the reference standard. For Refixia&reg;, polyethylene glycol (PEG) may cause interference in the one-step coagulation test, but not in the chromogenic test. Certain aPTT reagents such as Cephascreen&reg; and SynthaFax&reg; have been proven in laboratory studies to be worthwhile for reliable monitoring after the infusion of Refixia&reg;. However, it is recommended that silicon based reagents not be used as they may result in overestimates. The chromogenic test is not affected by PEG and the FIX kits ROX FACTOR IX and BIOPHEN Factor IX have in laboratory studies proven their worth for use with nonacog beta pegol. They can be used for reliable monitoring after the administration of Refixia&reg;.</p><p>&nbsp;</p><p><u>Posology</u></p><p>One International Unit (IU) of factor IX activity is equivalent to the amount of factor IX in a milliliter of normal human plasma.</p><p>&nbsp;</p><p><em><u>Prophylaxis</u></em></p><p>40 IU/kg body weight once weekly.</p><p>Adjustments of doses and administration intervals may be considered based on achieved FIX levels and individual bleeding tendency. The trough levels achieved with the weekly 40 IU/kg dosing regimen are summarised in section 5.2.</p><p>&nbsp;</p><p>Patients on prophylaxis who forget a dose are advised to take their dose upon discovery and thereafter continue with the usual once weekly dosing schedule. A double dose should be avoided.</p><p>&nbsp;</p><p><em><u>On-demand treatment</u></em></p><p>Dose and duration of the substitution therapy depend on the location and severity of the bleeding, see Table 1 for dosing guidance in bleeding episodes.</p><p>&nbsp;</p><p>Table 1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of bleeding episodes with Refixia<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_a024c1fa-0876-46e9-bc22-3ac91e45a081 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Degree of severity of bleeding</strong></p></td><td><p><strong>Recommended dose IU/kg of Refixia&reg;</strong></p></td><td><p><strong>Dosing recommendations</strong></p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Hemarthrosis at an early stage, muscle bleeding or bleeding in the oral cavity</p><p>Advanced hemarthrosis, muscle bleeding, or hematomas</p></td><td><p>40</p></td><td><p>A single dose is recommended.</p></td></tr><tr><td><p>Severe or life-threatening bleeding.</p></td><td><p>80</p></td><td><p>Additional doses of 40 IU/kg may be administered.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><em><u>Surgery</u></em></p><p>The dose level and dosing intervals for surgery depend on the procedure and local practice. Refer to Table 2 for general recommendations.</p><p>&nbsp;</p><p>Table 2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment in surgery with Refixia&reg;<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_9566d716-8c11-41bc-af0a-0c13fdf05cf2 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Type of surgery</strong></p></td><td><p><strong>Recommended dose IU/kg body weight</strong></p></td><td><p><strong>Dosing recommendations</strong></p></td></tr><tr><td><p>Minor operations, including the extraction of teeth</p></td><td><p>40</p></td><td><p>Additional doses may be administered as needed.</p></td></tr><tr><td rowspan="2"><p>Major surgery.</p></td><td><p>80</p></td><td><p>Pre-operative dose.</p></td></tr><tr><td><p>40</p></td><td><p>Consider two repeated doses of 40 IU/kg (at intervals of 1-3 days) within the first week after surgery.</p><p><strong>&nbsp;</strong></p><p>Due to the long half-life of Refixia&reg;, the product can be administered once a week after the first week of the postoperative period until bleeding stops and healing is achieved.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;&nbsp;&nbsp; <em><u>Paediatric population</u></em></p><p><em><u>&nbsp;</u></em></p><p>&nbsp;&nbsp;&nbsp; In children, the same dose is recommended as in adults: 40 IU/kg of body weight.</p><p><u>Method of administration</u> Intravenous use.</p><p>&nbsp;</p><p>Refixia&reg; is administered by intravenous bolus injection over several minutes after reconstitution of the powder for injection with the histidine solvent. The rate of administration should be determined by the patient&rsquo;s comfort level up to a maximum injection rate of 4 ml/min.</p><p>&nbsp;</p><p>For instructions on how to reconstitute the medicinal product prior to administration, see section 6.6.</p><p>&nbsp;</p><p>Appropriate training is recommended prior to administration of the product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Known allergic reaction to hamster protein.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>In order to improve traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p><strong>&nbsp;</strong></p><p><u>Hypersensitivity</u></p><p>As with all protein products for intravenous use, hypersensitivity reactions typical of allergy are also possible with Refixia&reg;. The preparation contains trace amounts of hamster proteins. Patients should be advised to discontinue the use of the medicinal product immediately in the event of signs of hypersensitivity and to contact the treating physician. You must be informed of the first signs of hypersensitivity reactions, including hives, generalized urticaria, chest tightness, wheezing, low blood pressure and anaphylaxis.</p><p>&nbsp;</p><p>In case of anaphylactic shock, current medical standards of shock treatment should be followed.</p><p><u>Inhibitors</u></p><p>After repeated treatment with human coagulation factor IX products, patients should be</p><p>monitored for the development of neutralising antibodies (inhibitors) that should be quantified in Bethesda Units (BU) using appropriate biological testing.</p><p>&nbsp;</p><p>There have been reports in the literature showing a correlation between the occurrence of a factor IX inhibitor and allergic reactions. Therefore, patients experiencing allergic reactions should be evaluated for the presence of an inhibitor. It should be noted that patients with factor IX inhibitors may be at an increased risk of anaphylaxis with subsequent challenge with factor IX.</p><p>&nbsp;</p><p>Due to the risk of allergic reactions that may occur with factor IX preparations, the first administration of factor IX should be performed under medical supervision according to the treating physician&rsquo;s judgment so that appropriate medical care can be provided in case of allergic reactions.</p><p>&nbsp;</p><p>In case of residual FIX activity levels, there is a risk of interference when performing the Nijmegen modified Bethesda assay for inhibitor testing. Therefore a pre-heating step or a wash-out is recommended in order to ensure detection of low-titre inhibitors.</p><p>&nbsp;</p><p><u>Thromboembolism</u></p><p>Due to the potential risk of thrombotic complications, clinical monitoring for early signs of thrombotic and consumption coagulopathy should be initiated by appropriate biological testing when administered to patients with liver disease, postoperative patients, neonates, or patients at risk of thrombotic phenomena or DIC. In these situations, the benefits of treatment with Refixia&reg; must be balanced against the risk of these complications.</p><p>&nbsp;</p><p><u>Cardiovascular event</u></p><p>In patients with existing cardiovascular risk factors, substitution therapy with FIX may increase the cardiovascular risk.</p><p>&nbsp;</p><p><u>Nephrotic syndrome</u></p><p>Nephrotic syndrome has been reported following attempted treatment for immunological tolerance induction with factor IX in patients with hemophilia B and often a history of allergic reaction.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Catheter-related complications</u></p><p>If a central venous access device (CVAD) is required, the risk of CVAD-associated complications, including local infection, bacteremia, and thrombosis at the catheter insertion site, should be considered.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The listed warnings and precautions apply to both adults and children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interactions of human coagulation factor IX (rDNA) preparations with other medicinal products have been reported.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Animal reproductive studies have not been conducted with factor IX. Due to the rare occurrence of hemophilia B in women, there is no clinical experience with the use of factor IX during pregnancy and breastfeeding. Therefore, factor IX should only be used during pregnancy and lactation if clearly indicated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Refixia&reg; has no influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>Hypersensitivity or allergic reactions (including angioedema, burning and stinging at the infusion site, chills, flushing, generalised urticaria, headache, hives, hypotension, lethargy, nausea, restlessness, tachycardia, tightness of the chest, tingling, vomiting, wheezing) have been observed rarely with recombinant factor IX products and may in some cases progress to severe anaphylaxis (including shock). In some cases, these reactions have developed to severe anaphylaxis, and have &nbsp;occurred in close temporal association with development of factor IX inhibitors (see also section 4.4). Nephrotic syndrome has been reported following attempted immunological tolerance induction with factor IX inhibitors in patients with hemophilia B and a history of allergic reaction.</p><p>&nbsp;</p><p>Very rarely development of antibodies to hamster protein with related hypersensitivity reactions has been observed.</p><p>&nbsp;</p><p>Patients with hemophilia B may develop neutralizing antibodies (inhibitors) to factor IX. The occurrence of such inhibitors manifests as an inadequate clinical response. In such cases, contact with a specialized hemophilia center is recommended.</p><p>&nbsp;</p><p>There is a potential risk of thromboembolic episodes following the administration of factor IX preparations, with a higher risk for low purity preparations. The use of low purity factor IX preparations has been associated with cases of myocardial infarction, disseminated intravascular coagulation, venous thrombosis and pulmonary embolism. The use of high purity factor IX such as Refixia&reg; is rarely associated with such adverse effects.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>The table below is based on MedDRA Organ Classes (SOC and Preferred Term Level).</p><p>&nbsp;</p><p>Frequencies are defined as follows: very common (&ge;1/10); common (&ge;1/100, &lt;1/10); uncommon (&ge;1/1,000, &lt;1/100); rare (&ge;1/10,000, &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p>Within each frequency class, adverse reactions are listed in order of decreasing severity.</p><p>&nbsp;</p><p>&nbsp;</p><p>A total of 115 previously treated patients (PTPs) and 50 previously untreated patients (PUPs) with moderate or severe haemophilia B have been exposed to Refixia for a total of 434 patient years in the completed and on-going clinical trials.</p><p>&nbsp;</p><p><strong>Table 3&nbsp;&nbsp;&nbsp;&nbsp; Frequency of adverse reactions in clinical trials </strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>System Organ Class </strong></p></td><td><p><strong>Adverse reaction </strong></p></td><td><p><strong>Frequency </strong></p></td></tr><tr><td><p>Blood and lymphatic system disorders</p></td><td><p>Factor IX inhibition</p></td><td><p>Common*</p></td></tr><tr><td><p>Immune system disorders</p></td><td><p>Hypersensitivity</p><p>Anaphylactic reaction</p></td><td><p>Common</p><p>Common*</p></td></tr><tr><td><p>Cardiac disorders</p></td><td><p>Palpitations</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Gastrointestinal disorders</p></td><td><p>Nausea</p></td><td><p>Common</p></td></tr><tr><td><p>Skin and subcutaneous tissue disorders</p></td><td><p>Pruritus**</p><p>Rash</p></td><td><p>Common</p><p>Common</p></td></tr><tr><td><p>General disorders and administration site conditions</p></td><td><p>Fatigue</p><p>Hot flush</p><p>Injection site reactions***</p></td><td><p>Common</p><p>Uncommon</p><p>Common</p></td></tr></tbody></table><p>* Frequency based on occurrence in PUP trial (N=50)</p><p>**Pruritus includes the terms pruritus and ear pruritus</p><p>***Injection site reactions include injection site pain, infusion site pain, injection site swelling, injection site erythema and injection site rash.</p><p>&nbsp;</p><p><u>Description of selected adverse effects</u></p><p>Factor IX inhibition and anaphylactic reactions have not been observed in PTPs, and frequencies are therefore based on an ongoing PUP trial with 50 patients. In this trial, Factor IX inhibition occurred in 4/50 (8%) and anaphylactic reaction occurred in 1/50 (2%) categorising these events as common. The case with anaphylactic reaction occurred in a patient that also developed Factor IX inhibition.</p><p>&nbsp;</p><p><u>Peadiatric population</u></p><p>Frequency, type and severity of adverse reactions in children are expected to be similar as in adults.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p>The National Pharmacovigilance and Drug Safety Centre (NPC):</p><p>o Fax: +966-11-205-7662</p><p>o&nbsp; SFDA call centre 19999</p><p>o&nbsp; Toll free phone: 8002490000</p><p>o&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong>Overdoses up to 169 IU/kg have been reported in clinical trials. No symptoms associated with overdoses have been reported.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antihaemorrhagics, blood coagulation factor IX, ATC code: B02BD04. <u>Mechanism of action</u></p><p>Refixia is a purified recombinant human factor IX (rFIX) with a 40 kDa polyethylene-glycol (PEG) conjugated to the protein. The average molecular weight of Refixia is approximately 98 kDa and the molecular weight of the protein moiety alone is 56 kDa. Upon activation of Refixia, the activation peptide including the 40 kDa polyethylene-glycol moiety is cleaved off, leaving the native activated factor IX molecule.</p><p>&nbsp;</p><p>Factor IX is a single chain glycoprotein. It is a vitamin-K dependent coagulation factor and it is synthesised in the liver. Factor IX is activated by factor XIa and by factor VII/tissue factor complex. Activated factor IX, in combination with activated factor VIII, activates factor X. Activated factor X converts prothrombin into thrombin. Thrombin then converts fibrinogen into fibrin and a clot is formed. Haemophilia B is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor IX and results in profuse bleeding into joints, muscles, or internal organs, either spontaneously or as a result of accidental or surgical trauma. By replacement therapy the plasma levels of factor IX are increased, thereby enabling a temporary correction of the factor deficiency and correction of the bleeding tendencies.</p><p>&nbsp;</p><p><u>Clinical efficacy</u></p><p>The clinical trial programme included one phase 1 trial and five phase 3 multicentre, non-controlled trials. All patients had severe (factor IX level &lt; 1%) or moderately severe (factor IX level &le; 2%) haemophilia B.</p><p>&nbsp;</p><p>Of note, annualised bleeding rate (ABR) is not comparable between different factor concentrates and between different clinical trials.</p><p>&nbsp;</p><p><em><u>Prophylaxis</u></em></p><p>One hundred one of the previously treated patients and previously untreated patients across all age-groups were treated with a weekly prophylactic dose of 40 IU/kg where 40 (40%) of these patients had no bleeding episodes (see details below).</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Pivotal trial</u></em></p><p>The pivotal trial included 74 adolescent (13&ndash;17 years) and adult (18&ndash;65 years) previously treated patients (PTPs). The trial included one open-label on-demand arm with treatment for approximately 28 weeks and two prophylaxis treatment arms with single-blind randomisation to either 10 IU/kg or 40 IU/kg once-weekly for approximately 52 weeks. When comparing the 10 IU/kg and 40 IU/kg treatments, the annualised bleeding rate for patients in the 40 IU/kg arm was found to be 49% lower than the bleeding rate (95% CI: 5%;73%) for patients in the 10 IU/kg arm (p&lt;0.05).</p><p>&nbsp;</p><p>The median (IQR) overall ABR in patients (13&ndash;65 years) treated with a prophylactic dose of 40 IU/kg once weekly was 1.04 (0.00; 4.01) whereas the traumatic ABR was 0.00 (0.00; 2.05), joint ABR was 0.97 (0.00; 2.07) and spontaneous ABR was 0.00 (0.00; 0.99).</p><p>&nbsp;</p><p>In this pivotal trial in adolescent and adult patients, there were 70 breakthrough bleeding episodes for 16 out of 29 patients in the 40 IU/kg prophylaxis arm. The overall success rate for treatment of breakthrough bleeds was 97.1% (67 out of 69 evaluated bleeds). A total of 69 (98.6%) of the 70 bleeding episodes were treated with one injection. Bleeding episodes were treated with Refixia at 40 IU/kg for mild or moderate bleeds.</p><p>&nbsp;</p><p>In 29 adult and adolescent patients treated, 13 patients with 20 target joints were treated for one year with a weekly prophylactic dose of 40 IU/kg. Eighteen out of these 20 joints (90%) were no longer considered target joints at the end of the trial.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>On-demand treatment</u></em></p><p>In the pivotal trial there was a non-randomised arm where 15 patients were treated in an on-demand regimen with 40 IU/kg for mild or moderate bleeds and 80 IU/kg for severe bleeds. The overall success rate (defined as excellent or good) for treatment of bleeds was 95% with 98% of the bleeds treated with one or two injections.</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>Previously treated patients (PTPs)</p><p>&nbsp;</p><p>The efficacy and safety of Refixia for prophylaxis and treatment of bleeds were evaluated in an open-label, single arm, non-controlled phase 3 trial. In the main phase of the paediatric PTP trial, 25 patients initially enrolled at 0 to 12 years of age received routine prophylactic administration of Refixia 40 IU/kg once weekly for 52 weeks. The patients were stratified into two age groups; 12 patients were 0 to 6 years and 13 patients 7 to 12 years at the time of signing informed consent. Twenty-two patients continued on to the extension phase and out of those, 12 patients had up to 8 years of routine prophylactic treatment. Due to the long trial duration several patients crossed age-groups and 10 patients that were initially enrolled as &le; 6 years also contributed to the age category of 7-12 years. Main efficacy results in patients &le; 12 years separated by main and extension phase are summarised in table 4.</p><p>&nbsp;</p><p><strong>Table 4: Annualised Bleeding Rate (ABR) in the Paediatric PTP Trial - Main &amp; Extension Phase &ndash; actual age groups</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td colspan="2"><p><strong>Main Phase</strong></p></td><td colspan="2"><p><strong>Extension Phase</strong></p></td></tr><tr><td><p><strong>Age of patient*</strong></p></td><td><p><strong>&le; 6 years N=12</strong></p></td><td><p><strong>7-12 years N=14</strong></p></td><td><p><strong>&le; 6 years N=10</strong></p></td><td><p><strong>7-12 years N=20</strong></p></td></tr><tr><td><p><strong>Mean treatment period (years)</strong></p></td><td><p>0.86</p></td><td><p>0.92</p></td><td><p>2.39</p></td><td><p>3.09</p></td></tr><tr><td><p><strong>Total ABR</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Poisson-estimated mean (95% CI)</p></td><td><p>0.97 (0.50; 1.89)</p></td><td><p>2.10 (1.34; 3.30)</p></td><td><p>1.05 (0.65; 1.69</p></td><td><p>0.58 (0.21; 1.64)</p></td></tr><tr><td><p><strong>Age of patient* </strong></p></td><td><p><strong>&le; 6 years </strong></p><p><strong>N=12 </strong></p></td><td><p><strong>7-12 years </strong></p><p><strong>N=14 </strong></p></td><td><p><strong>&le; 6 years </strong></p><p><strong>N=10 </strong></p></td><td><p><strong>7-12 years </strong></p><p><strong>N=20 </strong></p></td></tr><tr><td><p>Median (IQR)</p></td><td><p>0.00 (0.00; 1.99)</p></td><td><p>2.00 (0.00; 3.02)</p></td><td><p>0.00 (0.00; 1.65)</p></td><td><p>0.15 (0.00; 1.29)</p></td></tr></tbody></table><p>*Some patients contributed to both age groups.</p><p><strong>&nbsp;</strong></p><p>For the main and extension phase of the trial together, the overall median/poisson-estimated ABR was 0.55/1.02 (95% CI: 0.68; 1.54) in patients &le; 6 years and 0.52/0.84 (95% CI: 0.41; 1.75) in patients 7-12 years. The median/poisson-estimated ABR was 0/0.2 (95% CI: 0.09; 0.47) and 0/0.23 (95% CI: 0.05; 0.96) for spontaneous bleeds as well as 0.53/0.82 (95% CI: 0.55; 1.23) and 0.33/0.56 (95% CI: 0.25; 1.27) for traumatic bleeds in patients &le; 6 years and patients 7-12 years, respectively. Treatment success (defined as excellent or good response) was concluded for 88.6% and 93.7% of bleeding episodes that occurred during prophylaxis in patients &le; 6 years and patients 7-12 years, respectively. Five out of 25 patients (20%) did not have any bleeds throughout the trial.The mean annual consumption for prophylaxis was 2 208.6 (SD: 78.8) IU/kg and 2 324.8 (SD: 83.3) IU/kg for patients &le; 6 years and patients 7-12 years, respectively. Two patients had target joints at baseline, which were considered resolved during the main phase. None of the patients developed new target joints in the trial.</p><p>&nbsp;</p><p>Previously untreated patients (PUPs)</p><p>&nbsp;</p><p>The efficacy and safety of Refixia for prophylaxis and treatment of bleeds were evaluated in an open-label, single-arm multicentre non-controlled phase 3 trial. In the main phase of the paediatric PUP trial, 47 out of 50 patients &lt; 6 years old received 40 IU/kg once weekly and 38 patients continued on to the extension phase. Main efficacy results separated by main and extension phase are summarised in table 5.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Table 5: Annualised Bleeding Rate (ABR) in the Paediatric PUP Trial - Main and Extension</strong></p><p><strong>Phase</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>Main Phase N=47</strong></p></td><td><p><strong>Extension Phase N=38</strong></p></td></tr><tr><td><p><strong>Mean treatment period (years)</strong></p></td><td><p>0.75</p></td><td><p>2.23</p></td></tr><tr><td><p><strong>Total ABR</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Poisson-estimated mean (95% CI)</p></td><td><p>0.82 (0.34 ; 1.98)</p></td><td><p>0.58 (0.35 ; 0.96)</p></td></tr><tr><td><p>Median (IQR)</p></td><td><p>0.00 (0.00 ; 1.02)</p></td><td><p>0.00 (0.00 ; 0.88)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>The overall median ABR was 0 for spontaneous, traumatic, and joint bleeding episodes. For the trials main and extension phase the median/poisson-estimated ABR was 0.25/0.65 (95% CI: 0.34; 1.25) for PUPs on prophylaxis. The poisson-estimated ABRs for spontaneous and traumatic bleeds were 0.14 (95% CI: 0.05; 0.43) and 0.2 (95% CI: 0.05; 0.81) throughout the trial period, respectively (the median ABRs was 0 for both).46.8% of PUPs did not experience any bleeding events. None of the paediatric patients developed target joints in the trial. The overall success rate (defined as excellent or good) for treatment of bleeds in previously untreated patients was 96% (135 out of 140). Of the 140 treated bleeds observed in 34 (68%) out of 50 patients, 124 (89%) of the bleeds were resolved with 1 injection and 13 (9%) of the bleeds were resolved with 2 injections of Refixia.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><u>Overall haemostatic efficacy </u></p><p>Bleeding episodes were treated with Refixia at 40 IU/kg for mild or moderate bleeds or 80 IU/kg for severe bleeds, where one bleed was evaluated as severe. An overall assessment of haemostatic efficacy was performed by the patient or caretaker (for home treatment) or study site investigator (for treatment under health care professional supervision) using a 4-point scale of excellent, good, moderate, or poor.</p><p>The overall success rate (defined as excellent or good) for treatment of bleeds in previously treated patients was 92% (626 out of 683). Of the 677 treated bleeds observed in 84 (80%) of the 105 patients, 590 (86%) of the bleeds were resolved with 1 injection and 70 (10%) of the bleeds were resolved with 2 injections of Refixia.</p><p>&nbsp;</p><p>The success rate and dose needed for treatment of the bleeding episodes were independent of the localisation of the bleed. The success rate for treatment of bleeding episodes was also independent of whether the bleed was traumatic or spontaneous of nature.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Surgery</u></p><p>Three trials, of which one trial was a dedicated surgery trial, included in total 15 major and 26 minor surgery procedures (patients aged 13 to 56 years). Haemostatic effect of Refixia during surgery was confirmed with a success rate of 100% in the 15 major surgeries in the trials. All evaluated minor surgeries were performed successfully.</p><p>&nbsp;</p><p>In a dedicated surgery trial, the efficacy analysis included 13 major surgical procedures performed in 13 previously treated adult and adolescent patients. The procedures included 9 orthopaedic, 1 gastrointestinal, and 3 surgeries in the oral cavity. The patients received 1 pre-operative injection of 80 IU/kg on the day of surgery, and post-operatively, injections of 40 IU/kg. A pre-operative dose of 80 IU/kg Refixia was effective and no patients required additional doses on the day of surgery. In the post-surgery period Day 1 to 6 and Day 7 to 13, the median number of additional 40 IU/kg doses administered was 2.0 and 1.5, respectively. The mean total consumption of Refixia during and after surgery was 241 IU/kg (range: 81&ndash;460 IU/kg).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Refixia&reg; has an extended half-life compared to unmodified factor IX. All pharmacokinetic studies of Refixia&reg; were conducted in previously treated patients with hemophilia B (factor IX &le;2%). Plasma samples were analyzed using the one-stage coagulation test.</p><p>&nbsp;</p><p>Steady-state pharmacokinetic parameters for adolescents and adults are shown in Table 5.</p><p>&nbsp;</p><p>Table 6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Steady state pharmacokinetic parameters of Refixia (40 IU/kg) in adolescents and adults PTPs (geometric mean (CV%))<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_48a09703-0de1-46dd-a4d2-2acd7e8bb7df \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>PK Parameter</strong></p></td><td><p><strong>13&ndash;17 years N=3</strong></p></td><td><p><strong>&ge;18 years N=6</strong></p></td></tr><tr><td><p>Half-life (t<sub>1/2</sub>) (hours)</p></td><td><p>103 (14)</p></td><td><p>115 (10)</p></td></tr><tr><td><p>Incremental Recovery (IR) (IU/ml per IU/kg)</p></td><td><p>0.018 (28)</p></td><td><p>0.019 (20)</p></td></tr><tr><td><p>Area under the curve (AUC)<sub>0-168h</sub> (IU*hours/ml)</p></td><td><p>91 (22)</p></td><td><p>93 (15)</p></td></tr><tr><td><p>Clearance (CL) (ml/hour/kg)</p></td><td><p>0.4 (17)</p></td><td><p>0.4 (11)</p></td></tr><tr><td><p>Mean residence time (MRT) (hours)</p></td><td><p>144 (15)</p></td><td><p>158 (10)</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Volume of distribution (Vss) (ml/kg)</p></td><td><p>61 (31)</p></td><td><p>66 (12)</p></td></tr><tr><td><p>Factor IX activity 168 h post dosing (IU/ml)</p></td><td><p>0.29 (19)</p></td><td><p>0.32 (17)</p></td></tr></tbody></table><p>Clearance = body weight adjusted clearance; Incremental recovery = incremental recovery 30 min post dosing, Volume of</p><p>distribution = body weight adjusted volume of distribution at steady state. CV = coefficient of variation.</p><p>&nbsp;</p><p>In all patients evaluated in the steady-state PK study, activity levels were above 0.24 IU/mL with weekly administration of 40 IU/kg of factor IX 168 hours post dose.</p><p>&nbsp;</p><p>Single-dose pharmacokinetic parameters of Refixia are listed by age in Table 7.</p><p>&nbsp;</p><p>&nbsp;</p><p>Table 7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Single-dose pharmacokinetic parameters of Refixia (40 IU/kg) in PTPs by age<!--[if supportFields]><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_3197a889-db26-4e7c-a4be-9abf7bc3eda0 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>(geometric mean (CV%))<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_0441d6af-69cd-49c0-b16f-e12ef8e21c5a \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>PK Parameter</strong></p></td><td><p><strong>0&ndash;6 years N=12</strong></p></td><td><p><strong>7&ndash;12 years N=13</strong></p></td><td><p><strong>13&ndash;17 years N=3</strong></p></td><td><p><strong>&ge;18 years N=6</strong></p></td></tr><tr><td><p>Half-life (t<sub>1/2</sub>) (hours)</p></td><td><p>70 (16)</p></td><td><p>76 (26)</p></td><td><p>89 (24)</p></td><td><p>83 (23)</p></td></tr><tr><td><p>Incremental Recovery (IR) (IU/ml per IU/kg)</p></td><td><p>0.015 (7)</p></td><td><p>0.016 (16)</p></td><td><p>0.020 (15)</p></td><td><p>0.023 (11)</p></td></tr><tr><td><p>Area under the curve (AUC)<sub>inf</sub> (IU*hours/ml)</p></td><td><p>46 (14)</p></td><td><p>56 (19)</p></td><td><p>80 (35)</p></td><td><p>91 (16)</p></td></tr><tr><td><p>Clearance CL (ml/hour/kg)</p></td><td><p>0.8 (13)</p></td><td><p>0.6 (22)</p></td><td><p>0.5 (30)</p></td><td><p>0.4 (15)</p></td></tr><tr><td><p>Mean residence time (MRT) (hours)</p></td><td><p>95 (15)</p></td><td><p>105 (24)</p></td><td><p>124 (24)</p></td><td><p>116 (22)</p></td></tr><tr><td><p>Volume of distribution (Vss) (ml/kg)</p></td><td><p>72 (15)</p></td><td><p>68 (22)</p></td><td><p>59 (8)</p></td><td><p>47 (16)</p></td></tr><tr><td><p>Factor IX activity 168 h post dosing (IU/ml)</p></td><td><p>0.08 (16)</p></td><td><p>0.11 (19)</p></td><td><p>0.15 (60)</p></td><td><p>0.17 (31)</p></td></tr></tbody></table><p>Clearance = body weight adjusted clearance; Incremental recovery = incremental recovery 30 min post dosing, Volume of distribution = body weight adjusted volume of distribution at steady state. CV = coefficient of variation.</p><p>&nbsp;</p><p>As expected, body weight adjusted clearance in paediatric and adolescent patients was higher compared to adults. No dose adjustment was necessary for paediatric or adolescent patients.</p><p>&nbsp;</p><p>The mean trough levels at steady state are presented in Table 8; based on all pre-dose measurements taken every 8 weeks at steady state for all patients on once weekly dosing of 40 IU/kg.</p><p>&nbsp;</p><p>Table 8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Refixia&reg; factor IX trough levels* (40 IU/kg) by age at steady state<!--[if supportFields]><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_03123a77-9d17-42a1-be9d-e593aa82eea7 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><table border="1" cellspacing="0" cellpadding="0" style="width:432px"><tbody><tr><td style="width:112px"><p>&nbsp;</p></td><td style="width:78px"><p><strong>0&ndash;6 years</strong></p></td><td style="width:79px"><p><strong>7&ndash;12 years</strong></p></td><td style="width:81px"><p><strong>13&ndash;17 years</strong></p></td><td style="width:81px"><p><strong>18&ndash;65 years</strong></p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>N=12</strong></p></td><td><p><strong>N=13</strong></p></td><td><p><strong>N=9</strong></p></td><td><p><strong>N=20</strong></p></td></tr><tr><td><p>Estimated mean</p><p>factor IX trough</p><p>levels IU/ml</p><p>(95% CI)</p></td><td><p>0.15</p><p>(0.13;0.18)</p></td><td><p>0.19</p><p>(0.16;0.22)</p></td><td><p>0.24</p><p>(0.20;0.28)</p></td><td><p>0.29</p><p>(0.26;0.33)</p></td></tr></tbody></table><p>* Factor IX trough level = factor IX activity measured at all visits prior to the following weekly dose (5 to 10 days post dose).</p><p>&nbsp;</p><p>Pharmacokinetics were investigated in 16 adult and adolescent patients of which 6 were normal weight (BMI 18.5&ndash;24.9 kg/m<sup>2</sup>) and 10 were overweight (BMI 25&ndash;29.9 kg/m<sup>2</sup>). There were no apparent differences in the pharmacokinetic profiles between normal weight and overweight patients.</p><p>&nbsp;</p><p>In the paediatric PTP trial, the Factor IX mean trough levels at steady state were within the range of mild haemophilia (i.e. 0.05&ndash;0.4 IU/ml), independent of age.</p><p>&nbsp;</p><p>In the paediatric PUP trial, the estimated mean trough level at steady state was 0.15 IU/ml in patients &lt; 6 years old, i.e., within the range of mild haemophilia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A juvenile animal neurotoxicity study was conducted to evaluate the potential neurotoxicity of Refixia when intravenously administered 120-1 200 IU/kg/twice weekly in immature male rats from 3 to 13 weeks of age (corresponding to 2 to 16 years of age in humans), followed by a 13-week treatment-free period. The doses were 6-60 times higher than the weekly clinical dose of 40 IU/kg. PEG was detected by immunohistochemical staining in the choroid plexus, pituitary, circumventricular organs, and cranial motor neurons. Dosing Refixia to juvenile rats did not result in any functional or pathological effects, as measured by neurobehavioural/neurocognitive tests, including motor activity, sensory function, learning and memory as well as growth, sexual maturation, and fertility.</p><p>&nbsp;</p><p>In a repeat dose toxicity study in monkeys, mild and transient body tremors were seen 3 hours post dosing and abated within 1 hour. These body tremors were seen at doses of Refixia (3 750 IU/kg), which were more than 90 times higher than the recommended dose for humans (40 IU/kg). No mechanism behind the tremors was identified. Tremors have not been reported in the clinical trials.</p><p>&nbsp;</p><p>Non-clinical data reveal no concern for humans based on conventional safety pharmacology and repeated dose toxicity studies in rats and monkeys.</p><p>&nbsp;</p><p>In repeat dose toxicity studies in rats and monkeys, 40 kDa polyethylene-glycol (PEG) was detected by immunohistochemical staining in epithelial cells of choroid plexus in the brain. This finding was not associated with tissue damage or abnormal clinical signs.</p><p>&nbsp;</p><p>In distribution and excretion studies in mice and rats, the 40 kDa polyethylene-glycol (PEG) moiety of Refixia was shown to be widely distributed to and eliminated from organs, and excreted via plasma in urine (42&ndash;56%) and faeces (28&ndash;50%). Based on modelled data using observed terminal half-lives (15&ndash;49 days) in rat tissue distribution studies, the 40 kDa polyethylene-glycol (PEG) moiety will reach steady state levels in all human tissues within 1&ndash;4.5 years of treatment.</p><p>&nbsp;</p><p>The exposure ratios for PEG in the choroid plexus, measured in animals at the no observed adverse effect level (NOAEL) versus predicted clinical PEG-exposure, ranged from 5-fold in the juvenile rat neurotoxicity study to 6-fold in the 26-week repeat dose toxicity study in adult rats.</p><p>&nbsp;</p><p>Long-term studies in animals to evaluate the carcinogenic potential of Refixia, or studies to determine the effects of Refixia on genotoxicity, fertility, development, or reproduction have not been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Powder</u></p><p>Sodium chloride</p><p>Histidine</p><p>Sucrose</p><p>Polysorbate 80</p><p>Mannitol</p><p>Sodium hydroxide (for pH adjustment)</p><p>Hydrochloric acid (for pH adjustment)</p><p><u>Solvent</u></p><p>Histidine</p><p>Water for injections</p><p>Sodium hydroxide (for pH adjustment)</p><p>Hydrochloric acid (for pH adjustment)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, Refixia&reg; must not be mixed or reconstituted with solvents other than the accompanying histidine solution.</p><p>&nbsp;</p><p>Do not administer reconstituted Refixia&reg; through the same tubing and containers as other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened 

30 months. During the shelf life Refixia may be stored up to 30 °C for a single period not 
exceeding 1 year. Once the product has been taken out of the refrigerator the product must not be returned to the refrigerator. Please record the beginning of storage at room temperature on the 
product carton. 

After reconstitution 

Chemical and physical in-use stability have been demonstrated for 24 hours stored in a refrigerator 
(2 °C – 8 °C) and 4 hours stored at room temperature (≤ 30 °C) protected from light. 

From a microbiological point of view, the reconstituted product should be used immediately. If not 
used immediately, in-use storage times and conditions prior to use are the responsibility of the users 
and would normally not be recommended for longer than 4 hours stored at room temperature (≤ 30 °C) or 24 hours in a refrigerator (2 °C – 8 °C), unless reconstitution has taken place under controlled and validated aseptic conditions. Store the reconstituted medicinal product in the vial.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C). Do not freeze.</p><p>Store in the original package in order to protect from light.</p><p>Keep out of the sight and reach of children.</p><p>For storage at room temperature and storage conditions after reconstitution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each pack contains:</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 glass vial (type I) with powder and chlorobutyl rubber stopper</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 sterile vial adapter for reconstitution</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 pre-filled syringe of 4 ml histidine solvent with backstop (polypropylene), a rubber plunger (bromobutyl) and a tip cap with a stopper (bromobutyl)</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 plunger rod (polypropylene). Pack size of 1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Refixia&reg; should be administered intravenously after reconstitution of the powder with the solvent provided in the injection syringe. After reconstitution, the solution appears to be a clear and colorless solution that is free of visible particles. The reconstituted medicinal product should be visually inspected for particulate matter and discoloration prior to administration. Do not use solutions that are cloudy or have deposits.</p><p>&nbsp;</p><p>The rate of administration should depend on the patient&rsquo;s condition, with a maximum injection rate of 4 mL/min.</p><p>&nbsp;</p><p>You will also need an infusion set (tubing and butterfly needle), sterile alcohol wipes, gauze pads, and patches. These materials are not included with Refixia&reg;.</p><p>&nbsp;</p><p>Always use an aseptic technique.</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:rect id="Rectangle_x0020_104" o:spid="_x0000_s1026"
 style='position:absolute;left:0;text-align:left;margin-left:70.8pt;
 margin-top:15.45pt;width:38.5pt;height:.5pt;z-index:251661312;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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=
" fillcolor="black" stroked="f">
 <w:wrap anchorx="page"/>
</v:rect><![endif]-->Disposal</p><p>Dispose of the syringe containing the infusion set and vial with the adapter for the vial safely after injection. Dispose of any unused product and other waste materials according to local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Novo Nordisk A/S 
Novo Allé
DK-2880 Bagsværd 
Denmark
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nov/2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>